DaVita's Sell-Off Is the Setup, Not the Story

The market just threw DaVita to the wolves. The stock has plummeted roughly 27% from its August high of $247 to the low-$180s, wiping out more than $4 billion of market value in a matter of weeks. TD Cowen's Ryan Langston upgraded the name from Hold to Buy this morning and raised his price target to $220 from $201, citing market-position gains. The upgrade got no traction. Shares are still sliding.

The headline narrative says DVA is falling because of flat guidance, cost inflation, and Medicare payment uncertainty. That sounds ominous. But the operating numbers from Q2 don't match the tape. Free cash flow nearly doubled. Treatment volume is accelerating. Margins are holding.

The market is pricing a business in trouble. The cash-flow path says otherwise.

The proof point: free cash flow

Q2 free cash flow was $256 million, up from $157 million a year ago. That is not a cosmetic improvement. On a trailing-twelve-month basis, free cash flow is running above $1.6 billion — up nearly 25% year-over-year. Operating cash flow is $2.19 billion. Capital expenditures, at $583 million, are contained.

Free cash flow is the metric that forces a recheck. It doesn't care about the 2027 Medicare payment debate, the ACA subsidy cliff, or revenue-per-treatment headwinds. It measures what the business actually converted into cash after all the bills were paid. And it jumped.

DaVita also reaffirmed full-year 2026 guidance: adjusted operating income of $2.15 to $2.25 billion (midpoint $2.2 billion), adjusted diluted EPS of $14.10 to $15.20 (midpoint $14.65), and free cash flow of $1.0 to $1.25 billion. That free-cash-flow range, applied to today's market cap of $11.5 billion, implies a yield of 8.7% to 10.9%. For a dialysis operator with 15.1% ROIC and 56 basis points of treatment-volume growth, that is not a number the market can keep ignoring.

Why the stock fell anyway

Three things scared investors after Q2 results landed on August 4th.

Revenue per treatment declined $1.72 sequentially, from $417.59 in Q1 to $415.87 in Q2. Management attributed it to payor-mix shifts — specifically, fewer patients with commercial insurance as ACA subsidies expire. They see roughly $40 million of headwind in 2026 and another $70 million in 2027. Management expects slightly negative RPT growth in H2.

G&A expenses rose 10% in the quarter, from $320 million to $331 million. Patient-care costs grew above the expected range year-to-date. That's the second worry: costs are not decelerating as fast as the volume growth should allow.

Third, the competitive pickup from closed Fresenius clinics was weaker than expected. Fewer patients admitted than the model assumed.

Taken together, these three items created the impression that the growth engine is stalling. The market doesn't tolerate flatness after a stock has more than doubled over six months. And flat guidance after a 110% year-to-date run is a fast track to getting sold out of.

But flat guidance after a parabolic run is not the same thing as a broken thesis. The operating trajectory is still positive: 56 basis points of treatment-volume growth, $4.02 EPS versus a consensus of $3.92, operating income up roughly 5% year-over-year on an enterprise basis. The Q2 free-cash-flow result of $256 million, more than triple the prior-year quarter, is the number that deserves more attention than the sequential RPT dip.

The misread

The market is treating DaVita like a cost-structure story. That's the wrong frame. It's a volume-and-efficiency story with a regulatory tailwind that hasn't arrived yet.

The expanded HD (hemodialysis) rollout is the piece that will shift the long-term curve, even though management was clear that the financial impact won't register until 2028. DaVita secured supply of medium cut-off dialyzers compatible with existing machines — meaning the technology can be deployed broadly without significant capital investment. The clinical goal is non-inferiority to hemodiafiltration on all-cause mortality and major cardiovascular events. If the mortality benefit materializes, treatment volume growth moves from the low single digits into a structurally higher band. That's not a near-term driver, but it is a real optionality that the selloff is throwing away.

More immediately, the phosphate-binder transition into the Medicare dialysis bundle is already working. The number of patients on over-the-counter substitutes like TUMS has declined by more than 50%. This is a clinical improvement that also stabilizes revenue, even as the overall RPT number ticks down.

Valuation and the bridge

At $180, DaVita trades at roughly 12.3x full-year 2026 adjusted EPS midpoint of $14.65. That is well below the trailing P/E of 13.6 and below the forward P/E of 15.9 the market was willing to pay just weeks ago. The stock trades at 8.8x EV/EBITDA on a trailing basis and 0.71x on the PEG ratio — a measure that compares the P/E to earnings growth. A PEG below 1.0 means the stock is cheaper than its growth rate would suggest.

The enterprise value stands at $21.6 billion, and with $1.6 billion in trailing free cash flow, the FCF yield is roughly 7.4%. Add in $348 million of share repurchases in Q2 alone (2.2 million shares at an average of $155), and the per-share math compounds further.

TD Cowen's $220 target is a rebound number, not a full-revaluation number. It assumes the stock recovers from its post-earnings capitulation but doesn't demand a multiple expansion. At 15x the $14.65 EPS midpoint, you get $220. That's not an aggressive rerating — it's a return to the multiple the market was pricing before the selloff.

AInvest's aggregate signal still labels the stock a Hold, with a composite analysis rating of 3.84 out of 5. The broader analyst consensus, spread across eight analysts, remains neutral at Hold with an average target of $220.71. The market hasn't changed its mind. It's just cheaper now.

What would break the setup

The thesis hinges on three things holding together. First, treatment-volume growth needs to stay in the 25-to-50 basis-point range for the full year, as management guided. If volume decelerates — from higher mortality, fewer Fresenius pickups, or missed treatment rates climbing further — the volume engine stalls.

Second, costs need to decelerate in H2 as management expects. Total cost per treatment is guided to grow 1.25% to 2.25% for the full year. If G&A continues its 10% trajectory or patient-care costs don't bend down, margins compress and the FCF story erodes.

Third, the 2027 ESRD payment update from CMS can't come in significantly worse than the current proposal. Management says the proposed rate already tracks below industry cost trends. A harsher final rule would pressure operating income for 2027 and beyond.

If any of those three lines of evidence flips — volume stalls, costs accelerate, or CMS delivers a punishing payment update — the thesis is broken. Cut without ego.

The market priced DaVita like a company whose growth was stalling. The numbers say the business is generating more cash, growing volume, and executing on a clinical expansion that will compound. The selloff is tape pain, not business pain. At 12.3x forward earnings and a PEG of 0.71, the price has done the heavy lifting for anyone willing to hold through the noise.

The $220 target is a recovery floor. If FCF hits the top end of guidance and volume growth stays in the range, there's room above it. If costs bend and volume accelerates toward the upper end of the 50-basis-point range, the rerating is faster.

The tripwire is simple: full-year treatment-volume growth below 25 basis points, or H2 cost-per-treatment growth above 2.25%. If either happens, the inflection narrative is stale. Otherwise, the market's doing the work of pricing the old story while the business moves on to the next one.